Zobrazeno 1 - 10
of 216
pro vyhledávání: '"Richard A. Hubner"'
Autor:
Daniel Netto, Melissa Frizziero, Victoria Foy, Mairéad G. McNamara, Alison Backen, Richard A. Hubner
Publikováno v:
Current Oncology, Vol 31, Iss 9, Pp 5206-5223 (2024)
Pancreatic ductal adenocarcinoma (PDAC) is a significant cause of cancer-associated mortality, with a rising global incidence. A paucity of strong predictive risk factors mean screening programmes are difficult to implement. Historically, a lack of i
Externí odkaz:
https://doaj.org/article/82cdbede92d547bc8b5e3d4f02cac346
Autor:
Victoria Foy, Mairéad G. McNamara, Juan W. Valle, Angela Lamarca, Julien Edeline, Richard A. Hubner
Publikováno v:
Current Oncology, Vol 30, Iss 9, Pp 8665-8685 (2023)
The treatment of advanced unresectable HCC (aHCC) remains a clinical challenge, with limited therapeutic options and poor prognosis. The results of IMbrave150 and HIMALAYA have changed the treatment paradigm for HCC and established immune checkpoint
Externí odkaz:
https://doaj.org/article/e6075971c8d843248347bb5a70df88af
Autor:
Mairéad G. McNamara, Jayne Swain, Zoe Craig, Rohini Sharma, Olusola Faluyi, Jonathan Wadsley, Carys Morgan, Lucy R. Wall, Ian Chau, Nick Reed, Debashis Sarker, Jane Margetts, Daniel Krell, Judith Cave, Sharmila Sothi, Alan Anthoney, Christopher Bell, Alkesh Patel, Jamie B. Oughton, David A. Cairns, Wasat Mansoor, Angela Lamarca, Richard A. Hubner, Juan W. Valle
Publikováno v:
EClinicalMedicine, Vol 60, Iss , Pp 102015- (2023)
Summary: Background: The prognosis for patients with poorly-differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) is poor. A recognised first-line (1L) treatment for advanced disease is etoposide/platinum-based chemotherapy with no stan
Externí odkaz:
https://doaj.org/article/17e61c62deeb4eef9d3d7c4b9df3c376
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Neuroendocrine neoplasms (NENs) are rare malignancies arising most commonly in the gastrointestinal and bronchopulmonary systems. Neuroendocrine carcinomas (NECs) are a subgroup of NENs characterised by aggressive tumour biology, poor differentiation
Externí odkaz:
https://doaj.org/article/733af2b9707a4c1d8e811a72c0688cc5
Autor:
Sarah Clelland, Christina L. Nuttall, Helen E. Stott, Joseph Cope, Natalie L. Barratt, Kelly Farrell, Manyi V. Eyong, Jack P. Gleeson, Angela Lamarca, Richard A. Hubner, Juan W. Valle, Mairéad G. McNamara
Publikováno v:
Healthcare, Vol 11, Iss 20, p 2802 (2023)
Advanced pancreatic cancer is associated with a poor prognosis, often less than 1 year. Honest prognosis discussions guide early community palliative care services input, facilitating timely advance care planning and improving quality of life. The ai
Externí odkaz:
https://doaj.org/article/1ae44ad74f7743bb8ce29cca07591869
Autor:
Mairéad G. McNamara, Melissa Frizziero, Timothy Jacobs, Angela Lamarca, Richard A. Hubner, Juan W. Valle, Eitan Amir
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: There is no standard second-line treatment for patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma (EP-PD-NEC). This study explored data evaluating second-line treatment in these patients. Methods: A sear
Externí odkaz:
https://doaj.org/article/ac9dacadd8cb4122b077bd15b826da88
Autor:
Jaseela Chiramel, Alison C. Backen, Rille Pihlak, Angela Lamarca, Melissa Frizziero, Noor-ul-Ain Tariq, Richard A. Hubner, Juan W. Valle, Eitan Amir, Mairéad G. McNamara
Publikováno v:
International Journal of Molecular Sciences, Vol 18, Iss 5, p 909 (2017)
Overexpression of epidermal growth factor receptors (EGFR) occurs in >90% of pancreatic ductal adenocarcinomas (PDACs) and is associated with a poorer prognosis. A systematic review of electronic databases identified studies exploring the addition of
Externí odkaz:
https://doaj.org/article/2ac0cd4aa1bf4fa282ccb678be137acb
Autor:
Jianming Xu, Ken Kato, Eric Raymond, Richard A Hubner, Yongqian Shu, Yueyin Pan, Sook Ryun Park, Lu Ping, Yi Jiang, Jingdong Zhang, Xiaohong Wu, Yuanhu Yao, Lin Shen, Takashi Kojima, Evgeny Gotovkin, Ryu Ishihara, Lucjan Wyrwicz, Eric Van Cutsem, Paula Jimenez-Fonseca, Chen-Yuan Lin, Lei Wang, Jingwen Shi, Liyun Li, Harry H Yoon
Publikováno v:
The Lancet Oncology. 24:483-495
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25681c4067a9cbbd551fcdcbe9553991
https://doi.org/10.1016/s1470-2045(23)00108-0
https://doi.org/10.1016/s1470-2045(23)00108-0
Autor:
Reem D Mahmood, Kathryn Graham, Jack Gleeson, Richard A Hubner, Juan W Valle, Mairéad G McNamara
Publikováno v:
Immunotherapy. 15:517-530
There is a critical need for novel therapies to treat patients with advanced biliary tract cancer (BTC). This systematic review summarizes the evidence-based knowledge for the potential role of PD-1 and PD-L1 monoclonal antibodies in the treatment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a148f5d111935fd16a7a6d651f1ec6a3
https://doi.org/10.2217/imt-2022-0190
https://doi.org/10.2217/imt-2022-0190
Autor:
Simon Gray, Angela Lamarca, Mairéad G. McNamara, Julien Edeline, Karen Piper‐Hanley, Juan W. Valle, Richard A. Hubner
Publikováno v:
Liver Cancer International. 4:13-27
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::daa601743f8d2f2b7edf846cfeacc829
https://doi.org/10.1002/lci2.62
https://doi.org/10.1002/lci2.62